WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Lopinavir/ritonavir pharmacokinetics have been fully investigated in adults and children. WHAT THIS STUDY ADDS: • Lopinavir/ritonavir population pharmacokinetics in 96 neonates and infants from birth to less than 2 years (1.16 to 10.4 kg) showed that CL/F and V/F were dependent on body weight on an allometric basis and post-menstrual age. AIMS: Because of immature hepatic metabolism, lopinavir could present specific pharmacokinetics in the first weeks of life. We aimed at determining the optimal dosing regimen in neonates and infants weighing 1 to 10.5 kg. METHODS: Lopinavir/ritonavir (LPV/r) pharmacokinetics were studied in 96 infants using a population approach. RESULTS A one-compartment model described LPV/r pharmacokinetics. Normalized to a 70 kg adult using allometry, clearance (CL/F) and distribution volume (V/F) estimates were 5.87|h(-1) 70 kg(-1) and 91.7|70 kg(-1). The relative bioavailabilty, F, increased with post-menstrual age (PMA) and reached 50% of the adult value at 39.7 weeks. CONCLUSIONS: Size and PMA explained some CL/F and V/F variability in neonates/infants. Based upon trough concentration limitations, suggested LPV/r dosing regimens were 40 mg 12 h(-1), 80 mg 12 h(-1) and 120 mg 12 h(-1) in the 1-2 kg, 2-6 kg and 6-10 kg group, respectively.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Lopinavir/ritonavir pharmacokinetics have been fully investigated in adults and children. WHAT THIS STUDY ADDS: • Lopinavir/ritonavir population pharmacokinetics in 96 neonates and infants from birth to less than 2 years (1.16 to 10.4 kg) showed that CL/F and V/F were dependent on body weight on an allometric basis and post-menstrual age. AIMS: Because of immature hepatic metabolism, lopinavir could present specific pharmacokinetics in the first weeks of life. We aimed at determining the optimal dosing regimen in neonates and infants weighing 1 to 10.5 kg. METHODS:Lopinavir/ritonavir (LPV/r) pharmacokinetics were studied in 96 infants using a population approach. RESULTS A one-compartment model described LPV/r pharmacokinetics. Normalized to a 70 kg adult using allometry, clearance (CL/F) and distribution volume (V/F) estimates were 5.87|h(-1) 70 kg(-1) and 91.7|70 kg(-1). The relative bioavailabilty, F, increased with post-menstrual age (PMA) and reached 50% of the adult value at 39.7 weeks. CONCLUSIONS: Size and PMA explained some CL/F and V/F variability in neonates/infants. Based upon trough concentration limitations, suggested LPV/r dosing regimens were 40 mg 12 h(-1), 80 mg 12 h(-1) and 120 mg 12 h(-1) in the 1-2 kg, 2-6 kg and 6-10 kg group, respectively.
Authors: K M L Crommentuyn; B S Kappelhoff; J W Mulder; A T A Mairuhu; E C M van Gorp; P L Meenhorst; A D R Huitema; J H Beijnen Journal: Br J Clin Pharmacol Date: 2005-10 Impact factor: 4.335
Authors: Ellen G Chadwick; Edmund V Capparelli; Ram Yogev; Jorge A Pinto; Brian Robbins; John H Rodman; Jie Chen; Paul Palumbo; Leslie Serchuck; Elizabeth Smith; Michael Hughes Journal: AIDS Date: 2008-01-11 Impact factor: 4.177
Authors: Gwenda Verweel; David M Burger; Nancy L Sheehan; Alina S Bergshoeff; Adilia Warris; Linda C van der Knaap; Gertjan Driessen; Ronald de Groot; Nico G Hartwig Journal: Antivir Ther Date: 2007
Authors: Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Daniel Gonzalez; Laura P James; Amira Al-Uzri; Miroslava Bosheva; Felice C Adler-Shohet; Susan R Mendley; John S Bradley; Claudia Espinosa; Eva Tsonkova; Kathryn Moffett; Lucila Marquez; Kari A Simonsen; Stefan Stoilov; Felix Boakye-Agyeman; Theresa Jasion; Christoph P Hornik; Robert Hernandez; Daniel K Benjamin; Michael Cohen-Wolkowiez Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191
Authors: Daniel Gonzalez; Paula Delmore; Barry T Bloom; C Michael Cotten; Brenda B Poindexter; Elisabeth McGowan; Karen Shattuck; Kathleen K Bradford; P Brian Smith; Michael Cohen-Wolkowiez; Maurine Morris; Wanrong Yin; Daniel K Benjamin; Matthew M Laughon Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.938
Authors: Hylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R Cressey; Martina Penazzato; Angela Colbers; David M Burger Journal: Ther Drug Monit Date: 2019-08 Impact factor: 3.681
Authors: Adrie Bekker; Helena Rabie; Nicolas Salvadori; Samantha du Toit; Kanchana Than-In-At; Marisa Groenewald; Isabelle Andrieux-Meyer; Mukesh Kumar; Ratchada Cressey; James Nielsen; Edmund Capparelli; Marc Lallemant; Mark F Cotton; Tim R Cressey Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Mark F Cotton; Sandi Holgate; Aurelie Nelson; Helena Rabie; Catherine Wedderburn; Mark Mirochnick Journal: J Int AIDS Soc Date: 2015-12-02 Impact factor: 5.396
Authors: D Gonzalez; C Melloni; R Yogev; B B Poindexter; S R Mendley; P Delmore; J E Sullivan; J Autmizguine; A Lewandowski; B Harper; K M Watt; K C Lewis; E V Capparelli; D K Benjamin; M Cohen-Wolkowiez Journal: Clin Pharmacol Ther Date: 2014-06-20 Impact factor: 6.903